Industry context
Amphastar Pharmaceuticals [AMPH]
Last Updated 23 Jun 2026 @ 16:00 (Exchange is closed)
Last: $19.53
6.55%
-0.41 (↑)
GaG Algo Score™
v1.0
Short
-0.41 (↑)
Medium
-1.91 (↑)
Long
-2.22 (↑)
Line
Pivot Data
Pivot Statistics
| Metric | Average | Median | Std Dev |
|---|---|---|---|
| Gain % | 16.78% | 15.41% | 6.13% |
| Loss % | -17.59% | -10.36% | 12.89% |
| Duration | 17.6d | 14d | 12.0d |
| Total Pivots Found | 13 |
| Gain/Loss Legs | 12 (6 Gain / 6 Loss) |
| Last Pivot | Top @ $20.53 on 2026-06-11 |
| Change since Last Pivot | $-1.00 (-4.87%) |
Next Pivot Prediction Last: $19.53
| Predicted Next Type | Bottom |
| Predicted Price (Avg) | $16.92 |
| Predicted Price (Median) | $18.40 |
| Predicted Price Range (~68%) | $14.27 - $19.56 |
| Change to Avg Target | $-2.61 (-13.38%) |
| Predicted Date (Avg) | 2026-06-28 |
| Predicted Date Range (~68%) | 2026-06-16 - 2026-07-10 |
| Basis | Based on 6 historical losses (Avg: -17.59%, Median: -10.36%, StdDev of Abs: 12.89%) and duration (Avg: 17.6 days, StdDev: 12.0 days) |
| Note | Ranges assume ~normal distribution & historical patterns repeat. Use with caution. |
AMPH surges on on normal volume.
Amphastar Pharmaceuticals (AMPH) stock price surged on Tuesday after the stock rose $1.200 (6.55%) from the previous session on normal volume. Showing significant relative strength, the stock rose today while the NASDAQ fell -2.21%. With 660 867 shares traded, volume yesterday reached $12.91M. This was 106 572 shares less than the prior day. Compared to the 10-day average of 666 814 shares, volume was less than the average.
Amphastar Pharmaceuticals signals
There is no conclusive signals given from RSI. The price is above the short-term average yet below the long-term average, with the short-term average still below the long-term average; signals are mixed. Market in Equilibrium: A state of indecision prevails across all timeframes, with signals mixed in the short- (-13.3%), medium- (-13.3%), and long-term (-13.3%) horizons. This balance between forces suggests a period of consolidation and the absence of a clear directional catalyst.
Amphastar Pharmaceuticals Support & Resistance Levels
The stock is trading above the closest support level at $19.50. approximately $0.0300 (0.15%) away. This suggests it is currently acting as a floor, consolidating near support.The sup dis das support s119.5 -
Amphastar Pharmaceuticals Evaluation
- Short score: -0.41
- Medium score: -1.91
- Long score: -2.22
Ownership flow
GetAGraph InsiderPower
Transactions
116
Buy power
2 401 859
Sell power
1 292 726
2026-06-02
Lee Howard
Unknown
2026-06-01
Prins Richard K
Unknown
2026-06-01
Prins Richard K
Unknown
2026-06-01
Lee Howard
Unknown
2026-06-01
Lee Howard
Unknown
Relationship map
Correlation snapshot
Event context
Volume and dividends
Long volume corr.
-0.45
Short volume corr.
-0.34
Positioning pressure
Short interest pressure
Short interest
8.16%
Of outstanding shares
Short float
10.77%
Of tradable float
Days to cover
4.73
Short interest divided by average volume
Squeeze probability
42.60%
-0.86% change
Short interest is worth monitoring, but the setup is not extreme.
Updated 2026-05-29Income profile
Dividend profile
Last Dividend
$0.300
2010-06-11
Next Dividend
$0
N/A
Avg. yearly yield
0.00%
Annually
Total paid
$0.600
2 payments
Sustainability
0
low (50.00%)
Growth potential
0
No dividend growth expected in the near future
Direction
0
Score based on dividend trend and payout behavior.
Yearly history
| Year | Dividend | Yield |
|---|---|---|
| - | $0 | 0.00% |
| - | $0 | 0.00% |
| - | $0 | 0.00% |
| - | $0 | 0.00% |
| - | $0 | 0.00% |
| - | $0 | 0.00% |
Recent payments
| Date | Dividend | Payment |
|---|---|---|
| 2010-06-11 | $0.300 | 2010-06-30 |
| 2009-06-11 | $0.300 | 2009-06-30 |
Earnings quality
Earnings history
Reported quarters
10
EPS beats
7
EPS misses
3
Avg. surprise
21.52%
| Period | Date | Actual EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|---|
| Q3/2025 | 2025-11-04 | - | - | - | - |
| Q2/2025 | 2025-08-06 | - | $0.710 | - | - |
| Q1/2025 | 2025-05-07 | $0.740 | $0.660 | 12.12% | 170.53M |
| Q4/2024 | 2025-02-27 | $0.920 | $1.010 | -8.91% | 186.52M |
| Q3/2024 | 2024-11-06 | $0.960 | $0.990 | -3.03% | 188.82M |
| Q2/2024 | 2024-08-07 | $0.940 | $0.770 | 22.08% | 182.39M |
| Q1/2024 | 2024-05-08 | $1.040 | $0.960 | 8.33% | 171.84M |
| Q4/2023 | 2024-02-28 | $0.880 | $0.930 | -5.38% | 178.11M |
Analyst view
Analyst targets
Consensus
$20.50
Median
$20.50
Low
$19.00
High
$22.00
News flow
Latest company news
Market coverage
zacks.com New Strong Sell Stocks for June 23rd Jun 23, 2026 marketbeat.com Amphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for Growth Jun 10, 2026 globenewswire.com Amphastar Pharmaceuticals, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses Jun 8, 2026 marketbeat.com Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Drag Jun 4, 2026Company releases
Company context
Company profile
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers Specialty Generic
Currency
USD
Amphastar Pharmaceuticals Inc established in 1996 and based in Rancho Cucamonga California functions as a biopharmaceutical enterprise The company is engaged in the creation production commercialization and distribution of both generic and proprietary pharmaceutical products which include injectables inhalants and intranasal formulations Its market presence extends across the United States China and France Amphastars operations are divided into two primary segments Finished Pharmaceutical Products and Active Pharmaceutical Ingredients API The companys extensive product portfolio encompasses a variety of crucial medications These feature Primatene Mist an overthecounter epinephrine inhaler for the temporary alleviation of mild asthma symptoms Enoxaparin a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis and Naloxone an essential treatment for opioid overdose Other significant offerings include emergency Glucagon injection kits Cortrosyn a diagnostic agent for adrenocortical insufficiency and Amphadase a bovinesourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs Amphastar additionally supplies Epinephrine injections for severe allergic reactions various lidocaine products such as a jelly for urological procedures and a topical solution for other applications Phytonadione injection Vitamin K1 for newborns and specialized emergency syringe products for hospital use Furthermore the company provides Morphine injections for patientcontrolled analgesia and Lorazepam injections for surgical and medical procedures More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects and Isoproterenol hydrochloride injection for mild or transient episodes of heart block Beyond its finished pharmaceutical goods Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API The company caters to a broad spectrum of healthcare providers including hospitals various care facilities clinics and physicians offices
Navigation